Endocrine Disruption Screening Market Share, Demand & Opportunities by 2034

Endocrine Disruption Screening Market Size and Forecast (2021 - 2034), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Assay Type (In-Vitro and In-Vivo), Application (Natural Materials and Synthetic Materials), Sources of Waste (Incineration and Landfill, Agricultural Runoff, Industrial and Municipal Effluents, Pulp Mill Effluents, Consumer Products, and Others), Method [Estrogen Receptor (ER) Transactivation, Androgen Receptor (AR) Transactivation, Androgen Receptor (AR) Modulation, Estrogen Receptor-Alpha (ER-Alpha) Binding, Estrogen Receptor-Beta (ER-Beta) Binding, Androgen Receptor (AR) Binding, Steroidogenesis, Aromatase Assay, and Others], and End User (Pharmaceutical and Biopharmaceutical Companies, Cosmetics and Household Product Companies, Food Industry, and Chemical Industry) and Geography

Historic Data: 2021-2024   |   Base Year: 2025   |   Forecast Period: 2026-2034
  • Report Date : Mar 2026
  • Report Code : TIPRE00025912
  • Category : Life Sciences
  • Status : Upcoming
  • Available Report Formats : pdf-format excel-format
  • No. of Pages : 150
Endocrine Disruption Screening Market Share, Demand & Opportunities by 2034
Report Date: Mar 2026   |   Report Code: TIPRE00025912
Buy Now
Page Updated: Feb 2026

The global endocrine disruption screening market size is expected to reach US$183.86 million by 2034 from US$141.94 million in 2025. The market is anticipated to register a CAGR of 2.92% during the forecast period of 2026–2034.

Endocrine Disruption Screening Market Analysis

The endocrine disruption screening market is transitioning from traditional single-endpoint toxicity testing toward mechanism-based assessment frameworks. To lead the endocrine disruption screening market, stakeholders need to shift from traditional single-endpoint toxicity tests to a framework based on mechanisms. The primary opportunity is to use high-throughput screening and AI-driven predictive modeling, which are both needed to meet the testing requirements set by REACH and the EPA. Manufacturers can focus on developing human-on-a-chip systems and advanced in-vitro receptor-binding assays. These methods help lower the costs and address ethical concerns related to animal testing, which delays the approval of new chemicals. It is also important to combine real-time bio-monitoring data with computational toxicology to make stronger safety claims. Expanding localized testing services in the Asia-Pacific region will enable stakeholders to capture substantial volume growth as environmental monitoring standards converge with those of Western regulations.

Endocrine Disruption Screening Market Overview

The endocrine disruption screening market covers a comprehensive spectrum of assay technologies and methodologies designed to identify chemicals that interfere with hormonal signaling. These substances, known as endocrine-disrupting chemicals (EDCs), are clinically and environmentally linked through their ability to mimic or block natural hormones, leading to reproductive, developmental, and metabolic disorders. There are three main types of assays used in screening: in vitro receptor transactivation, in vivo apical endpoint studies, and steroidogenesis assays. In the past, endocrine screening was mostly seen as a secondary check for toxicity; now it is moving toward a more proactive method called the Integrated Approach to Testing and Assessment (IATA). This market serves a global industrial base that is rapidly expanding due to the proliferation of synthetic materials in consumer goods and rising public scrutiny of chemical safety in agricultural runoff and industrial effluents.

Customize This Report To Suit Your Requirement

Get FREE CUSTOMIZATION

Endocrine Disruption Screening Market: Strategic Insights

endocrine-disruption-screening-market
  • Get Top Key Market Trends of this report.
    This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Endocrine Disruption Screening Market Drivers and Opportunities

Market Drivers:

  • Rising Regulatory Mandates and Global Safety Frameworks: Demand for screening services is rising due to strict EPA (EDSP) and OECD guidelines. These rules call for careful testing of pesticides and industrial chemicals to help prevent hormonal problems in people and wildlife.
  • Advancements in High-Throughput and In-Vitro Technologies: Next-generation receptor-binding assays, such as ER and AR transactivation, offer more sensitive detection and quicker results. These advances help make testing thousands of existing and new chemicals more efficient.
  • Shift Toward Holistic Environmental Impact Assessment: Healthcare and environmental systems are increasingly adopting early intervention models. By screening consumer products and industrial waste streams for endocrine activity early in the supply chain, regulators can prevent long-term public health crises related to endocrine-linked cancers and infertility.

Market Opportunities:

  • Expansion into Automated Computational Toxicology: Significant opportunities exist in replacing labor-intensive assays with AI-powered predictive models. This broadens the screening potential for companies with limited physical lab capacity and facilitates rapid risk prioritization.
  • Targeting Emerging Contaminants in Water and Soil: The development of specialized assays for agricultural runoff and pulp mill effluents represents an untapped frontier. Companies advancing these specialized field-testing agents can address the high unmet need for real-time environmental monitoring.
  • Integration with Precision Health and Bio-monitoring: Combining screening data with digital health platforms allows for the correlation of EDC exposure with population health trends. This integration enhances regulatory decisiveness and supports the development of "safer-by-design" synthetic materials.

Endocrine Disruption Screening Market Report Segmentation Analysis

The endocrine disruption screening market share is analyzed across various segments to provide a clearer understanding of its structure, growth potential, and emerging trends. Below is the standard segmentation approach used in most industry reports:

By Assay Type:

  • In-Vitro
  • In-Vivo

By Application:

  • Natural Materials
  • Synthetic Materials

By Source of Waste:

  • Incineration and Landfill
  • Agricultural Runoff
  • Industrial and Municipal Effluents
  • Pulp mill effluents
  • Consumer Products

By Method:

  • Estrogen Receptor Transactivation
  • Androgen Receptor Transactivation
  • Androgen Receptor Modulation
  • Estrogen Receptor-Alpha Binding
  • Estrogen Receptor-Beta Binding
  • Androgen Receptor Binding
  • Steroidogenesis
  • Aromatase Assays

By Geography:

  • North America
  • Europe
  • Asia Pacific
  • South & Central America
  • Middle East & Africa 

Endocrine Disruption Screening Market Regional Insights

The regional trends and factors influencing the Endocrine Disruption Screening Market throughout the forecast period have been thoroughly explained by the analysts at The Insight Partners. This section also discusses Endocrine Disruption Screening Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Endocrine Disruption Screening Market Report Scope

Report Attribute Details
Market size in 2025 US$ 141.94 Million
Market Size by 2034 US$ 183.86 Million
Global CAGR (2026 - 2034) 2.92%
Historical Data 2021-2024
Forecast period 2026-2034
Segments Covered By Assay Type
  • In-Vitro
  • In-Vivo
By Application
  • Natural Materials
  • Synthetic Materials
By Sources of Waste
  • Incineration and Landfill
  • Agricultural Runoff
  • Industrial and Municipal Effluents
  • Pulp Mill Effluents
  • Consumer Products
By Method
  • Estrogen Receptor Transactivation
  • Androgen Receptor Transactivation
  • Androgen Receptor Modulation
  • Estrogen Receptor-Alpha Binding
  • Estrogen Receptor-Beta Binding
  • Androgen Receptor Binding
  • Steroidogenesis
  • Aromatase Assay
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Creative Bioarray ? United States
  • Xenometrix AG ? Switzerland
  • Charles River ? United States
  • Eurofins Scientific ? Luxembourg
  • Smithers ? United States
  • SGS SA ? Switzerland
  • JRF Global ? India
  • M?rieux NutriSciences ? France
  • Alpha Analytical ? United States

Endocrine Disruption Screening Market Players Density: Understanding Its Impact on Business Dynamics

The Endocrine Disruption Screening Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.


endocrine-disruption-screening-market-cagr

  • Get the Endocrine Disruption Screening Market top key players overview

Endocrine Disruption Screening Market Share Analysis by Geography

Asia Pacific is expected to grow fastest in the coming years. Emerging markets in South & Central America, the Middle East, and Africa also have many untapped opportunities for contract research organizations (CROs) to expand.

The endocrine disruption screening market shows a different growth trajectory in each region due to factors such as healthcare infrastructure, regulatory environment, environmental awareness, and government initiatives. Below is a summary of market share and trends by region:  

1. North America

  • Market Share: Holds the largest market share due to strict EPA Endocrine Disruptor Screening Program (EDSP) mandates.
  • Key Drivers:
    • Strong presence of leading CROs and pharmaceutical giants
    • High investment in high-throughput screening (HTS) technologies
    • Early adoption of computational toxicology and in-silico modeling
  • Trends: Shift toward integrated in-vitro testing batteries to reduce reliance on long-term in-vivo rodent studies and accelerate safety assessments.

2. Europe

  • Market Share: Significant share driven by REACH regulations and ECHA safety standards.
  • Key Drivers:
    • There is widespread use of OECD-approved methods for ensuring chemical safety.
    • The government provides significant funding for research into alternatives to animal testing.
    • Cosmetics and personal care products are subject to strict regulations.
  • Trends: Increasing focus on the "Chemicals Strategy for Sustainability" to achieve a toxic-free environment by 2030 through proactive hazard identification.

3. Asia Pacific

  • Market Share: Fastest-growing region owing to rapid industrialization and expanding regulatory frameworks in China and India.
  • Key Drivers:
    • Urbanization is leading to stricter wastewater and industrial effluent monitoring.
    • Government-led environmental protection missions and "Green Chemistry" initiatives
    • Surge in domestic chemical manufacturing for global exports
  • Trends: Local adoption of international screening standards to facilitate the export of chemical products and cosmetics to highly regulated Western markets.

4. South and Central America

  • Market Share: Emerging market with growing focus on agricultural runoff and pesticide safety.
  • Key Drivers:
    • Large-scale agricultural sector requiring extensive pesticide toxicity screening
    • Public-private partnerships to modernize environmental monitoring laboratories
    • Rising awareness of hormonal health and reproductive safety in urban centers
  • Trends: Adoption of cost-effective, portable screening kits to monitor water quality and soil contamination in rural and farming communities.

5. Middle East and Africa

  • Market Share: Developing market with significant growth potential as environmental health policies mature.
  • Key Drivers:
    • National e-health and sustainability strategies in GCC countries
    • Increasing investment in desalination and wastewater treatment infrastructure
    • Expanding pharmaceutical production hubs in Egypt, Saudi Arabia, and South Africa
  • Trends: Implementation of endocrine screening as part of broader national health security and water safety programs, often utilizing automated immunoassay platforms.

Endocrine Disruption Screening Market Players Density: Understanding Its Impact on Business Dynamics

High Market Density and Competition

Competition is intensifying due to the presence of global laboratory leaders such as Eurofins Scientific, Charles River, and SGS SA. Specialized toxicology innovators and regional experts like Xenometrix AG (Switzerland) and JRF Global (India) also contribute to the increasingly crowded and technically demanding market landscape.

This competitive environment pushes vendors to differentiate through:

  • Screening assays are now developed with pre-validation by the OECD and EPA. This ensures international data acceptance and meets mutual acceptance of data (MAD) requirements.
  • Testing is now faster as automated platforms with multiple receptors and computer-based modeling have replaced traditional, labor-intensive cell-based assays.
  • New industrial hubs around the world now offer screening and analytical services. This shortens sample travel times and helps meet local chemical management rules.
  • Specialized tests are now available for specific endocrine pathways beyond just estrogen and androgen. These include tests for thyroid and steroidogenesis disruption.

Opportunities and Strategic Moves

  • Partner with chemical and agroscience manufacturers to support the early-stage identification of endocrine-disrupting properties, streamlining the path to global market registration.
  • Incorporate New Approach Methodologies (NAMs) and high-throughput screening (HTS) to reduce reliance on animal testing while increasing the speed of safety assessments for complex mixtures.

Major Companies operating in the Endocrine Disruption Screening Market are:

  • Creative Bioarray – United States
  • Xenometrix AG – Switzerland
  • Charles River – United States
  • Eurofins Scientific – Luxembourg
  • Smithers – United States
  • SGS SA – Switzerland
  • JRF Global – India
  • Mérieux NutriSciences – France
  • Alpha Analytical – United States

Disclaimer: The companies listed above are not ranked in any particular order.

Endocrine Disruption Screening Market News and Recent Developments

  • In January 2025, the U.S. EPA finalized a settlement to advance its Endocrine Disruptor Screening Program (EDSP) and introduced a new tracking website for FIFRA Data Call-In notices targeting high-priority conventional pesticides. The move accelerates endocrine data requirements and enhances regulatory transparency, supporting continued demand for endocrine disruption screening and compliance services.
  • In September 2024, UNEP and WHO convened an expert group to update the State of the Science Report on Endocrine Disrupting Chemicals (EDCs). The initiative enhances global scientific guidance and transparency, potentially influencing regulatory requirements and driving demand for endocrine disruption screening, testing, and compliance services.

Endocrine Disruption Screening Market Report Coverage and Deliverables

The "Endocrine Disruption Screening Market Size and Forecast (2021–2034)" report provides a detailed analysis of the market covering below areas:

  • Endocrine Disruption Screening Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
  • Endocrine Disruption Screening Market trends, as well as market dynamics such as drivers, restraints, and key opportunities
  • Detailed PEST and SWOT analysis
  • Endocrine Disruption Screening Market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
  • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments in the Endocrine Disruption Screening Market
  • Detailed company profiles

 


Frequently Asked Questions

The global endocrine disruption screening market is expected to grow from US$141.94 million in 2025 to US$183.86 million by 2034. The compound annual growth rate for 2026 to 2034 is projected at 2.92%.

The market is growing mainly because of strict regulations like the EPA Endocrine Disruptor Screening Program and OECD guidelines. Other key drivers are new high-throughput and in vitro assay technologies, along with more attention to early environmental and chemical safety checks.

In vitro and in vivo assays dominate the market. Key methods include estrogen and androgen receptor transactivation, receptor binding assays, steroidogenesis assays, aromatase assays, and androgen receptor modulation assays.

Key players include Creative Bioarray, Xenometrix AG, Charles River, Eurofins Scientific, Smithers, SGS SA, JRF Global, Mérieux NutriSciences, and Alpha Analytical.

North America holds the largest market share because of strict EPA rules and strong testing systems. The Asia Pacific region is growing the fastest, due to more industry, new regulations, and closer monitoring of wastewater and chemicals.
Mrinal Kerhalkar
Manager,
Market Research & Consulting

Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

  • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
  • PEST and SWOT Analysis
  • Market Size Value / Volume - Global, Regional, Country
  • Industry and Competitive Landscape
  • Excel Dataset

Testimonials

Reason to Buy

  • Informed Decision-Making
  • Understanding Market Dynamics
  • Competitive Analysis
  • Identifying Emerging Markets
  • Customer Insights
  • Market Forecasts
  • Risk Mitigation
  • Boosting Operational Efficiency
  • Strategic Planning
  • Investment Justification
  • Tracking Industry Innovations
  • Aligning with Regulatory Trends
Our Clients
Sales Assistance
US: +1-646-491-9876
UK: +44-20-8125-4005
Chat with us
DUNS Logo
87-673-9708
ISO Certified Logo
ISO 9001:2015
GDPR
CCPA